"The median survival in this select group is substantially better than the historical median survival for CUP patients when treated with empiric CUP regimens," said F. Anthony Greco, MD, Director of the Sarah Cannon Research Institute and senior author of the study.
"Targeted therapies for metastatic cancers require precise knowledge of both tissue origin and underlying disease pathways. CancerTYPE ID provides critical information on cellular context," said Mark Erlander, PhD, Chief Scientific Officer of bioTheranostics.
CancerTYPE ID is a 92-gene molecular classification test that has been shown to discriminate among tumor types that pose diagnostic dilemmas, including neuroendocrine subtypes often associated with metastasis. The test classifies 30 main tumor types, 54 subtypes and 106 different morphologies, covering more than 95 percent of all solid tumors.
"This study demonstrates both diagnostic and therapeutic utility of CancerTYPE ID in metastatic cancer management," said Richard Ding, Chief Executive Officer of bioTheranostics. "We are pleased to provide more evidence that CancerTYPE ID continues to set new standards in the emerging field of molecular cancer classifiers."
Advancing Molecular Diagnostics in Oncology
bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecul
|SOURCE bioTheranostics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved